Introduction
The incidence of resistance to antimicrobial agents has been a prime public health issue over the last decade, that influencing the monitoring and treatment of infections in nosocomial and health care-associated settings, and in the community. 1 Specifically, the emergence of extendedspectrum β-lactamase (ESBL) -producing bacteria such as E. coli and K. pneumoniae as the most prevalent ESBL producing bacterial that become major causative agents for increasing resistance to β-lactam antibiotics. 2 Because β-lactam antimicrobial agents are among the most widely used antibiotics to treat those infections. 3, 4 All ESBL producers confer resistance to all generations of cephalosporins, penicillins, and aztreonam (except for cephamycins or carbapenems) via hydrolysis of these antibiotics. The inactivation is done by antibiotic combination therapy using B-lactamase inhibitors with antibiotics such as clavulanic acid, sulbactam, or tazobactam.
important mechanism of B-lactam resistance in Enterobacteriaceae. 2 In addition, ESBL producing organisms display co-resistance to many other types of antibiotics resulting in limitation of treatment alternatives. 6, 7 The ESBL genes are mostly plasmid-encoded which can easily spread from one organism to another. 8 ESBLs are grouped into four classes A, B, C and D enzymes and eight subgroups according to their functional and structural characteristics. Cefotaximase (CTX-M), temoneira (TEM) and sulfhydryl variable (SHV) are a class A β-lactamases. 9 TEM and sulphydryl variable SHV are the most common types. However, CTX-M type is the major type in some countries. 10 Many ESBLs arise because of mutations in the natural B-lactamase related genes like TEM-1, TEM-2, and SHV-1 genes. 11 While these basic enzymes exist predominantly in Klebsiella species and E. coli. 12 Until now, more than 400 different ESBL variants have been identified. 13 Detection of ESBL is initially based on phenotypic tests, such as the double-disc synergy test and combined disc method. However, these tests are time-consuming and inhibited by the AmpC β-lactamases. Over the past years, PCR has replaced traditional phenotypic methods. 6 Determination of ESBL genes, including TEM and SHV, by molecular techniques in ESBL producing bacteria and their pattern of antimicrobial resistance can provide reliable information about their epidemiology and risk factors related to their infections. 13 Navon-Venezia and cowarkers 14 indicated that these phenotypic tests need to be monitored periodically, as their performance may change with the introduction of the new enzyme by such bacteria. The present study aimed to estimate the prevalence of ESBL producing E. coli and K. pneumoniae with detection of related SHV genes by PCR among patients admitted for treatment at Rezgari Teaching Hospital in Erbil City. In addition to investigating the antimicrobial resistance profile of those ESBL producers.
Study Design and Bacterial Isolates
The present study was conducted at Rizgary Teaching Hospital in Erbil City, Iraqi Kurdistan Region, in which the prevalence of ESBL-producing E. coli and K. pneumoniae strains were evaluated over a period of 5 months. From January the 10 th to June the 20 th 2016, a total of 120 consecutive non-repeated clinical isolates (101 E. coli, and 19 K. pneumoniae) were collected from different clinical specimens such as urine, tracheal aspirate, high vaginal swabs, wound swab and blood. The specimens were obtained by the clinical microbiology laboratory at a hospital as part of routine diagnostic activities. Isolates were identified to s p e c i e s l e v e l u s i n g s t a n d a r d microbiological methods. 15 All isolates were stored at -70° C in glycerol broth until tested. This project was approved at the first site by the Scientific and Research Ethics Committee at the College of Pharmacy, Hawler Medical University.
Identification and Characterization of Antimicrobial Susceptibility
In vitro susceptibility testing of all collected isolates to a wide range of antimicrobials was performed using VITEK 2 compact system, 15 an automated ID and susceptibility (AST) system (bioMe´rieux, USA). VITEK 2 system includes an Advanced Expert System (AES) with a high sensitivity and specificity values (94-100%) that considered rapid and reliable means for routine laboratory work that is widely used for identification and/or susceptibility testing. 16 15 Final results were interpreted using the Advanced Expert System (AES) (software version VT2-R05.04). Testing was repeated wherever suggested by the AES. 16, 17 Detection of ESBL by Phenotypic Method Each isolate was tested using the VITEK 2 system with the antimicrobial susceptibility test extend AST-EXN8 card. This system was designed to perform both screening and confirmatory tests for phenotypic detection of ESBL on the same plate. 17 The test comprises a panel of six wells containing ceftazidime 0.5 mg⁄ L, cefotaxime 0.5 mg⁄ L and cefepime 1.0 mg⁄ L, the rest of three wells were filled with same three antibiotics in combination with clavulanic acid (4, 4 and 10 mg⁄ L, respectively). Growth in each well was quantitatively assessed by means of an optical reader. The proportional reduction in growth in wells containing cephalosporin plus clavulanate compared with those containing the cephalosporin alone was considered to be indicative of ESBL production. All phenotypic interpretations of ESBLs were reported as a positive ESBL screening result. Strains were reported as ESBL-negative whenever phenotypic interpretations other than ESBLs were proposed by the AES.
5,18
Molecular Detection of ESBL Genes Conventional PCR was used for detection of the genes for SHV. Isolates sub-cultured from frozen stock using blood agar media. Cells were grown on blood agar plates for 24 h at 37°C, and few colonies were resuspended in 500ml of sterile distilled water. The bacterial cells were lysed by heating at 95°C for 10 min, and cellular debris was removed via centrifugation at 16,000rpmfor 2 min. The supernatant was used as the source of DNA template for PCR. 19, 20 About 5µl of DNA template was added to the final volume of 25 µl Mastermix (GoTaq® Green Master Mix, a premixed ready-to-use solution containing Taq DNA polymerase, dNTPs, MgCl 2 , and reaction buffers at optimal concentrations for efficient amplification of DNA templates) GoTaq® Green Master Mix(Promega M7122, USA). Primers were used previously by others The amplified products were separated in 1.2 percent agarose gel. The agarose gel was prepared by mixing 1.2g agarose powder with 100 mL 1xTBE buffer in a microwavable flask. The mixture was dissolved in a microwave for a few mins then left at room temperature to cool down to about 50 o C. Ethidium bromide was then added to a final concentration of 0.5 mg/ml. The agarose then poured into a gel tray with the good comb in place until it has completely solidified. A 100-1000 bp DNA molecular weight marker (Norgen Biotech Corp Cat. No. 11600) was used to measure the bands of amplified products. PCR product samples and the ladder were then loaded into the wells of the gel starting with the ladder into the first well. No positive and negative controls were used because the product size was known 768bp and confirmed by measuring its size using the ladder as a reference. The gel was then run at a voltage of 100 V until the dye line was approximately 75-80% of the way down the gel and was visualized the DNA fragments using a UV light camera in a dark room.
Statistical Analysis
The statistical package for the social science (SPSS 23 Chicago, IL, USA) was used to compare the mean value ± standard deviations (SD) of antibiotic resistance. The frequencies, percentages, and Chi-Square were used in the study, and a P value of ≤0.05 was considered as statistically significant. monitoring systems and prevention of the emergence and spread of ESBL-producing Enterobacteriaceae. 21 The misidentification of ESBLs by diagnostic laboratories could result in wrong therapy via unsuitable prescription of cephalosporins leading to failure in treatment and even causing death. 22 The accurate detection of ESBL producing microorganisms is a major clinical problem in the laboratories, requiring not only phenotypic tests but also genotypic tests for all genes associated with beta-lactamase production. 2 The prevalence of β-lactamase producers and the distribution of ESBL genotypes are different from one year to another and even vary greatly in different geographical areas. 23 High prevalence of ESBL among K. pneumoniae isolates has been detected in numerous studies. 2, 21, 24, 25 Similarly in this study, K. pneumoniae was the most frequently encountered ESBL-positive isolates (Table 1 ). From the current study, the overall proportion of ESBL-producing
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Regarding antibiotic susceptibility of SHV +ve E. coli and K. pneumoniae isolates, the present study shows that among 11 SHV +veisolates, all were resistant to Ampicillin, Ampicillin/Sulbactam, Trimethoprim/ Sulfamethoxazole, Gentamicin as well asoxyiminocephalosporins (100%). However, all isolates were susceptible to carbapenems and nitrofurantoin (100%). The majority of isolates showed a high degree of resistance to Ciprofloxacin with Levofloxacin (90.9%) and to Tobramycin (81.8%) but appeared to be susceptible to Piperacillin/Tazobactam (45.4%) as shown in Table 5 . The ESBL-producing bacteria have been dramatically spreading worldwide at an alarming rate, and the incidence of ESBL-producing Enterobacteriaceae has threatened the entire world in the current era. At present, the major challenge to infection control is requiring continuous E. coli and K. pneumoniae isolates was 76.6%. A similar finding was reported by other investigators in Iraq (73.9%). 5 In neighboring countries, the prevalence of infection with ESBL-producing Gram-negative bacteria varied from 89.8% in Iran, 26 31 .7% in Kuwait, 27 54.7% -61% in Turkey, 28, 29 50.8% in Jordan, 6 30.6% in Saudia Arabia 15 and 41% in the United Arab Emirates. 30 However, our results showed a higher prevalence compared to relative studies from India (27.6% -66.7%) 5, 31 and Kenya (6%). 2 The prime factors for increasing prevalence of ESBLs were attributed to extensive use of thirdgeneration cephalosporins, besides the lack of routine screening for ESBLproducer isolates or isolation guidelines for the infected patients. 20 Therefore, data produced from this study concerning in terms of these isolates resistance to cephalosporin antibiotics. Faced with the global emergence of antimicrobial resistance, several studies have been undertaken to assess the susceptibility of bacterial pathogens to different antibiotics. 5, 12, 16 These findings revealed that there is a widely spreading resistance to most of the available antibiotics, as shown in Table 2 . The highest resistance overall was observed against Ampicillin, oxyimino cephalosporin, and ampicillin/ sulbactam, while all isolates showed sensitivity towards carbapenems. In fact, ESBL-producer isolates showed significant higher resistant rate to the 3 rd and 4 th generation cephalosporin (100%) than non ESBL-producer isolates, while these results were comparable with what have been found in published literature. 5, 16, 26 The antimicrobial resistance displayed various results. All ESBL-producing E. coli and K.pneumoniae were significantly resistant to ampicillin, 3rd and 4th generations cephalosporins (%100). These results are consistent with the related studies in the same field. 1, 3, 14, 23 Furthermore, ESBLproducing isolates were highly resistant to ampicillin/sulbactam (65.2%), trimethoprim/ sulfamethoxazole (63%) and gentamicin (61.9%). These findings might be due to the fact that clinicians and other health care providers may be unaware of the problem of ESBL production by gram-negative bacilli resulting in inappropriate medication. 2 However all isolates showed sensitivity towards carbapenems (100%), The lowest rates of resistance in ESBL-producing isolates were observed for nitrofurantoin (5.4%), and piperacillin/tazobactam(13%) data are presented in Table 2 . Multi-drug resistant isolates showed to be greater among ESBL-producing isolates than non ESBLproducers. Similar findings were reported in a number of recent studies. 2, 5, 6, 26 Besides being associated with high morbidity and mortality, the treatment of infections caused by ESBL-producing isolates is becoming increasingly limited. ESBL genotypes were detected in 36.6%of ESBL-producing isolates of E.coli and K. pneumoniae. SHV genes were detected in 55.5% of K. pneumoniae isolates compared to the 28.5% detection rate within E. coli isolates. It is remarkable that SHV type ESBL was frequently found in K. pneumoniae. The similar finding reported in other studies. 21, [32] [33] [34] Interestingly, ESBLs are mostly detected in K. pneumoniae, as SHV-1 was originally characterized as a plasmid-mediated β -lactamase, some reports suggest that its production may be native to K. pneumoniae since it appears that some clinical K. pneumoniae strains encode SHV-1 β-lactamase production on their chromosomes. 22 The rate of SHVin this study was a little higher than that reported in a Turkish hospital (24.2%) all of which were K. pneumoniae isolates. 32 In another study, SHV (92.9%) was detected as the most prevalent ESBL type in K. pneumoniae isolates. 35 In Turkey, during 2004 and 2005, SHV was detected in (46.7%) E. coli, and K. pneumoniae isolates. 36 While in a study done in a Saudi Arabian tertiary hospital, 23.1% of the isolates harbored the SHV gene. 16 The rate of blaSHV in this study was higher than that reported in an Iranian hospital (5.5%) which were E. coli isolates. 26 Our findings show a lower rate than that reported in Macedonia (49.4%). 33 In different studies, the percentage of SHV gene in E. coli and K. pneumoniae were determined to be 23.1% 16 , 23.3% 37 and 4.3%. 6 These differences may be caused by several factors such as the type and number of the samples, the number of the isolates studied, genus and species of the isolates. 32 In our study, a detailed analysis of the 30 isolates of ESBL-producing E. coli and K. pneumoniae showed that 100% of SHV +ve isolates of E.coli and K. pneumoniae were resistance to betalactam antibiotics, oxyiminocephalosporins, G e n t a m y c i n , a n d T r i m e t h o p r i m / Sulfamethoxazole (Table 5) . A similar pattern of resistance by Gram-negative pathogens has been reported recently by investigators. 2, 5, 21 The highest rate of resistance in SHV +ve isolates was observed for Ciprofloxacin and Levofloxacin (90.9%). This may be attributed to misuse of Ciprofloxacin and restriction of aminoglycosides in our hospitals. The significantly lower proportion of SHV+ve isolates showing resistance to pepracillin/tazobactam (45.4%) compared to the amoxicillin/clavulanate resistance rate (63.6%), since SHV is more inhibited by tazobactam than clavulanate. The results agreed with a study done in Saudi Arabia. 21 The extraordinary genetic capacities of microbes have benefited from man's overuse of antibiotics by means of horizontal gene transmission to develop multiple mechanisms of resistance as a result of many years of unremitting selection pressure upon human applications of antibiotics. 38 
Conclusion
In conclusion, the great difference between ESBL and the spread of clinical isolates of E. coli and K. pneumoniae producing these enzymes refer that this is an important health issue in our region. Microbiology laboratories need to be alert to the correct identification and control of infections caused by such microorganisms. The widespread emergence and proliferation of SHV-type ESBLs is particularly noteworthy and may have important implications for clinical microbiology laboratories and physicians treating patients with serious infections caused by these isolates. The most active antimicrobial agent against both ESBL-producers and non ESBLproducer isolates were carbapenem in this study. It is, therefore, strongly recommended to consider carbapenems as the drug of choice for such multi-drug resistant ESBL-producing microorganisms. SHV type of ESBL genes was highly prevalent among E. coli and K. pneumoniae collected in Erbil city. Therefore, it is necessary to monitor for the spread of these resistance genes and to ensure careful antibiotic use in a hospital setting. Further research should be carried out to study in depth the distribution and evolution of ESBL and other related genes in these pathogens. In addition to that using a larger sample size from various hospitals across the city and different parts of the region to obtain a more representative picture.
